This Unpopular Dividend Stock Is a Buy
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% over the prior five years while the benchmark S&P 500 has delivered total returns of 97.5%, including dividends.
Source Fool.com



